文献速递妇科肿瘤

miR-143通过靶向调控K-ras基因表达抑制HeLa细胞增殖

[miR-143 inhibits cell proliferation through targeted regulating the expression of K-ras gene in HeLa cells].
PubMed 文献 · Zhonghua Zhong Liu Za Zhi · 2016-01-01

该研究探讨miR-143通过靶向调控K-ras基因对宫颈癌HeLa细胞增殖的影响。双荧光素酶报告实验证实miR-143靶向K-ras 3‘-UTR,HeLa细胞转染实验显示miR-143过表达下调K-ras蛋白并抑制细胞增殖;小样本宫颈癌组织中miR-143表达低于宫颈上皮内瘤变组织,K-ras蛋白表达高于宫颈上皮内瘤变组织。

要点

  • 双荧光素酶报告实验显示miR-143靶向调控K-ras基因3‘-UTR。
  • HeLa细胞中miR-143过表达下调K-ras蛋白并抑制细胞增殖。
  • 小样本宫颈癌组织中miR-143低表达、K-ras蛋白高表达。

核心结论

  • 体外实验中,miR-143可通过靶向调控K-ras基因表达抑制HeLa细胞的增殖活性。
  • 在小样本的人宫颈癌组织中,miR-143表达下调,K-ras表达上调。

研究设计与样本

  • 体外细胞实验:将含K-ras基因野生型3‘-UTR(K-ras-wt)或突变型3’-UTR(K-ras-mut)的荧光素酶报告载体分别与miR-143 mimic共转染HeLa细胞,用双荧光素酶报告系统验证靶向作用。
  • HeLa细胞分别转染miR-143 mimic(miR-143 mimic组)、mimic对照(阴性对照组)及miR-143 mimic加K-ras基因(miR-143 mimic+K-ras组),用RT-PCR检测miR-143表达,Western blot检测K-ras蛋白表达,MTT法检测细胞增殖活性。
  • 另检测人宫颈癌组织样本(n=5)和宫颈上皮内瘤变组织样本(n=5)中miR-143与K-ras蛋白的表达。

主要发现

  • 双荧光素酶报告实验显示,共转染miR-143 mimic显著降低K-ras-wt的荧光素酶活性,但不抑制K-ras-mut的荧光素酶活性。
  • 转染miR-143 mimic的HeLa细胞中miR-143表达显著高于转染mimic对照的HeLa细胞(3.31±0.45 vs 0.97±0.22,P<0.05)。
  • MTT实验显示,miR-143 mimic组细胞增殖活性显著低于阴性对照组(P<0.05),miR-143 mimic+K-ras组细胞增殖活性也显著低于对照组(P<0.05),但显著高于miR-143 mimic组(P<0.05)。
  • miR-143 mimic组、阴性对照组和miR-143 mimic+K-ras组的K-ras蛋白表达水平分别为最低、中等和最高(115.27±34.08、521.36±41.89和706.52±89.44,均P<0.05)。
  • 组织样本中,宫颈癌组miR-143表达显著低于宫颈上皮内瘤变组(0.32±0.06 vs 0.93±0.17,P<0.05);宫颈癌组K-ras蛋白表达显著高于宫颈上皮内瘤变组(584.39±72.34 vs 114.23±25.82,P<0.05)。

关键数值与推荐

  • 双荧光素酶报告实验:miR-143 mimic共转染降低K-ras-wt荧光素酶活性,但不抑制K-ras-mut荧光素酶活性。
  • HeLa细胞miR-143表达:miR-143 mimic组3.31±0.45 vs 阴性对照组0.97±0.22,P<0.05。
  • K-ras蛋白表达:miR-143 mimic组115.27±34.08、阴性对照组521.36±41.89、miR-143 mimic+K-ras组706.52±89.44,均P<0.05。
  • 组织表达:宫颈癌组miR-143 0.32±0.06 vs 宫颈上皮内瘤变组0.93±0.17,P<0.05;宫颈癌组K-ras蛋白584.39±72.34 vs 宫颈上皮内瘤变组114.23±25.82,P<0.05。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To explore the effect of microRNA miR-143 on the proliferation of cervical cancer HeLa cells through targeted regulating the expression of K-ras gene. Methods: The luciferase report carrier containing wild type 3'-UTR of K-ras gene (K-ras-wt) or mutated 3'-UTR of the K-ras (K-ras-mut) were co-transfected with iR-143 mimic into the HeLa cells respectively, and the targeting effect of miR-143 in the transfectants was verified by the dual luciferase report system. HeLa cells were also transfected with miR-143 mimic (miR-143 mimic group), mimic control (negative control group), and miR-143 mimic plus K-ras gene (miR-143 mimic+ K-ras group), respectively. The expression of miR-143 in the transfected HeLa cells was detected by real-time PCR (RT-PCR), and the expression of K-ras protein was detected by Western blot. The cell proliferation activity of each group was examined by MTT assay. In addition, human cervical cancer tissue samples (n=5) and cervical intraepithelial neoplasia tissue samples (n=5) were also examined for the expression of miR-143 and K-ras protein by RT-PCR and Western blot, respectively. Results: The luciferase report assay showed that co-transfection with miR-143 mimic decreased the luciferase activity of the K-ras-wt significantly, but did not inhibit the luciferase activity of the K-ras-mut. The expression of miR-143 in the HeLa cells transfected with miR-143 mimic was significantly higher than that in the HeLa cells transfected with the mimic control (3.31±0.45 vs 0.97±0.22, P<0.05). The MTT assay revealed that the cell proliferative activity of the miR-143 mimic group was significantly lower than that of the negative control group (P<0.05), and the cell proliferative activity of the miR-143 mimic+ K-ras group was also significantly lower than the control group (P<0.05) but higher than the miR-143 mimic group significantly (P<0.05). The expression levels of K-ras protein in the miR-143 mimic group, the negative control group and the miR-143 mimic+ K-ras group were lowest, moderate, and highest, respectively (115.27±34.08, 521.36±41.89, and 706.52±89.44, all P<0.05). In the tissue samples, the miR-143 expression in the cervical cancer group was significantly lower than that of the cervical intraepithelial neoplasia group (0.32±0.06 vs. 0.93±0.17, P<0.05); whereas the K-ras protein expression in the cervical cancer group was significantly higher than that in the cervical intraepithelial neoplasia group (584.39±72.34 vs. 114.23±25.82, P<0.05). Conclusions: In vitro, miR-143 can inhibit the proliferative activity of HeLa cells through targeted regulating the expression of K-ras gene. In human cervical cancer tissues of a small sample set, the expression of miR-143 is downregulated, and the expression of K-ras is upregulated.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. Qin HX, Cui HK, Pan Y, et al. [miR-143 inhibits cell proliferation through targeted regulating the expression of K-ras gene in HeLa cells]. Zhonghua Zhong Liu Za Zhi. 2016. PMID: 27998464. doi:10.3760/cma.j.issn.0253-3766.2016.12.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。